Ixazomib

3:34
The efficacy of a novel, triple combination in the treatment of MM
Shaji Kumar
1:25
Myeloma UK: exciting clinical trials investigating treatments for MM
Rakesh Popat
2:32
New therapies shaping the future of amyloidosis
Giampaolo Merlini
1:49
Real world data of ixazomib in combination with lenalidomide and dexamethasome
Rakesh Popat
1:37
Which is the best combination therapy in relapsed and refractory multiple myeloma?
Meletios Dimopoulos
2:36
What does the TOURMALINE-MM2 study tell us about the use of ixazomib in multiple myeloma?
Paul Richardson
11:38
Frontline treatment for young multiple myeloma patients
Gareth Morgan et al.
2:10
Changing the standard of care for elderly multiple myeloma patients
Maria-Victoria Mateos
3:48
KEYNOTE-183 trial of pembrolizumab in multiple myeloma: trial design and rationale
Jatin Shah
4:11
Multiple myeloma highlights from ASCO 2016: monoclonal antibodies and oral proteasome inhibitors
Joseph Mikhael
5:35
Treatment at first relapse in multiple myeloma: how to choose a drug?
Gareth Morgan
10:26
Myeloma 2016: Panel discussion on the application of genomics studies
Leif Bergsagel et al.
2:52
The role of proteasome inhibitors in multiple myeloma
Mohamad Mohty
7:15
ENDEAVOUR, ASPIRE and TOURMALINE-MM1 trial results for multiple myeloma
Michel Delforge
4:05
Mechanism of action of proteasome inhibitors
Michel Delforge
2:22
Recent drug approvals for the treatment of relapsed/refractory multiple myeloma
Paul Richardson
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals